On the stock market since 2008, it operates in the world of money and finance. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 59% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 68% a year on average.
Sales run at $167K a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 129 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $574K against $167K in annual sales.
The stock sits at $0.03. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, MNTR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MNTR is a high-risk stock — not yet profitable, and its future rides on its product catching on.